The companies formed the joint venture in 2008 to commercialize BioMérieux's IVD products and medical instruments in Japan.
The new company will develop microbiome diagnostics for multiple indications including inflammatory bowel disease and liver disorders.
Fulgent reached an agreement with two Chinese firms to establish a joint venture to offer genetic testing services in China.
The company will pay nearly $2.1 million to the liquidating trust for the now-bankrupt HDL in order to resolve outstanding debt from a former joint lab venture.
Partnering with Biodist Group, the South Korean molecular diagnostics firm is looking to move into non-human applications such as food safety testing.
Agilent will provide technology and training for the jointly-run lab, expanding on a 2011 deal to open a microarray technology center at Monash University Malaysia.
Emory and Eurofins, following their JV last year, plan to open several clinical genetics labs across the globe that draw on EGL's expertise.
Horizon Discovery will use its experience with gene editing, immunology, and oncology to develop immunotherapies based on Centauri's antibody conjugate technology.
The JV will be based in London with operations in Cambridge, Massachusetts and will develop new treatments for blood disorders, blindness, and congenital heart disease.
DiaGenomi offers a number of tests that combine DNA analysis with information about lifestyle and medical results to provide disease risk assessments.
Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.
Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.
China is embracing preimplantation genetic diagnosis, Nature News reports.
In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.